# Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

> **NCT01206296** · PHASE2 · TERMINATED · sponsor: **Medstar Health Research Institute** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Intraperitoneal Gemcitabine

## Key facts

- **NCT ID:** NCT01206296
- **Lead sponsor:** Medstar Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study suspended
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206296, "Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01206296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*